Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KLK1 | P06870 | 2/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | LDHB | P07195 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL31438646 | 1.00 | ACHE (0.38) | ACHEALDH1A1L3MBTL1KLK1KLK5 | |
| Trifluoroacetic Acid SCHEMBL7764428 | 1.00 | ACHE (0.38) | ACHEALDH1A1L3MBTL1KLK1KLK5 | |
| Trifluoroacetic Acid SCHEMBL4006098 | 0.88 | ACHE (0.33) | ACHEALDH1A1L3MBTL1KLK1KLK5 | |
| Trifluoroacetic Acid SCHEMBL6542389 | 0.88 | LMNA (0.39) | ACHEALDH1A1L3MBTL1KLK1KLK5 | |
| Trifluoroacetic Acid SCHEMBL19272425 | 0.87 | CYP1A2 (0.36) | KLK1KLK5CA2TSHRLMNA | |
| Trifluoroacetic Acid SCHEMBL2344616 | 0.87 | FAAH (0.38) | F2F11PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL29019097 | 0.87 | TP53 (0.35) | ALDH1A1F2F11PRSS1PRSS2 | |
| Trifluoroacetic Acid SCHEMBL3906649 | 0.86 | ALDH1A1 (0.46) | ACHEALDH1A1L3MBTL1LDHALDHB | |
| Trifluoroacetic Acid SCHEMBL934980 | 0.86 | ACHE (0.54) | ACHEALDH1A1L3MBTL1LDHALDHB | |
| Trifluoroacetic Acid SCHEMBL15533970 | 0.86 | ACHE (0.54) | ACHEALDH1A1L3MBTL1LDHALDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115915795-A | Perovskite solar cell containing double-layer trifluoroacetate modification layer and preparation method thereof | 河北工业大学 | 2023-04-04 | — | — | CN | claimed |
| US-8425702-B2 | Precursor of an explosive composition including at least one ionic liquid and a method of desensitizing an explosive composition | ALLIANT TECHSYSTEMS INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20120024437-A1 | PRECURSOR OF AN EXPLOSIVE COMPOSITION INCLUDING AT LEAST ONE IONIC LIQUID AND A METHOD OF DESENSITIZING AN EXPLOSIVE COMPOSITION | ALLIANT TECHSYSTEMS INC. (US) | 2012-02-02 | — | — | US | claimed |
| US-8012277-B2 | Mixture with activator; desentization melt | ALLIANT TECHSYSTEMS INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20080251169-A1 | IONIC LIQUID, A METHOD OF SYNTHESIZING AN IONIC LIQUID, A PRECURSOR OF AN EXPLOSIVE COMPOSITION INCLUDING AT LEAST ONE IONIC LIQUID, AND A METHOD OF DESENSITIZING AN EXPLOSIVE COMPOSITION | ALLIANT TECHSYSTEMS INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| US-12516892-B2 | Inverted barocaloric effects | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| EP-4602126-A1 | INVERTED BAROCALORIC EFFECTS | President and Fellows of Harvard College (US) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024081374-A9 | INVERTED BAROCALORIC EFFECTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025101904-A1 | NOREPINEPHRINE TRANSPORTER-TARGETED PRODRUGS FOR CANCER THERAPY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Thereapeutics Pty LTD (AU) | 2025-02-20 | — | — | US | disclosed |
| CN-1351602-A | Novel Pharmaceutically Active Compounds | ASTRAZENECA AB (SE) | 2002-05-29 | — | — | CN | disclosed |
| EP-0805685-B1 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | MERCK & CO INC (US) | 2001-09-26 | — | — | EP | disclosed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | disclosed |
| CN-1237961-A | Aminoguanidines and alkoxyguanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 1999-12-08 | — | — | CN | disclosed |
| US-5854213-A | Antifungal cyclohexapeptides | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0805685-A4 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | MERCK & CO INC (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0805685-A1 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | Merck & Co., Inc. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022784-A1 | NOVEL ANTIFUNGAL CYCLOHEXAPEPTIDES | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059178-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | ACHE 4072/4885ALDH1A1 3547/4885L3MBTL1 542/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | ACHE 4712/4885ALDH1A1 2406/4885L3MBTL1 1179/4885 |
| US-12590083-B2 | Inhibitors of spinster homolog 2 (SPNS2) for use in therapy | SPNS2, SLC20A2, S1PR2 | ACHE 4514/4885ALDH1A1 4169/4885L3MBTL1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.